June 15, 2022, Correctseq got prize of “Top 10 Gene Therapy Companies of 2022 Future Healthcare VB100-Best Performing Companies in Value Fields” from VBDATA.CN, which held a conference titled“2022 Future Healthcare VB100”from June 14 to 18, 2022. Correctseq is considered as the most potential company in the gene therapy fields because of its innovative gene editing technology by investors and medias.
2022 Future Healthcare VB100, which started from 2015, is held by VB100, VBDATA.CN, VCbest Research. It is the Chinese first list which focuses on the unlisted companies of creative healthcare fields. The Best Performing Companies in Value Fields are selected through many kinds of methods such as investors and journalists’ interview, industry reports, etc. There is a multiple and comprehensive evaluation system containing capital attention, media attention, the focus of healthcare companies performing data yearly, the potential development of healthcare industry in the future.
Correctseq has the first base editing tool authorized by Chinese patents and a series of innovative base editing technology which can correct the mutated base gene. Its multiple pipelines for genetic diseases, tumor immunotherapy, metabolic diseases, and infectious diseases based on the base editing technology are well underway. Recently, Correctseq has developed an innovative base editing therapy using tBE(transformer Base Editor) for β-thalassemia. Compared with Cas Nuclease gene editing therapy, tBE exhibits higher editing efficiency and γ-globin induction, lower cytotoxicity and no off-target mutations. There is potential clinical value of the independent-developed base editing technology of Correctseq.
Recently, Correcseq got several prizes in healthcare field, giving recognition to its innovative gene editing technology and encourage it to create more gene editing therapies. Correctseq will focus on biotechnology innovation, research and development and is committed to use its innovative gene editing system to help people living with serious diseases.
About CorrectSequence Therapeutics
CorrectSequence Therapeutics aims to use our innovative gene editing system to help people living with serious diseases. We have developed multiple base editing systems and our base editors offer significant advantages in controlling off-target effects and improving in vivo editing efficiency. Multiple pipelines are well underway. The scientific co-founders of Correctseq focus on the frontier of gene editing field. Our R&D laboratory, CMC process development laboratory, and cGMP manufacturing facility are built with world-class standards, which strongly guarantees the rapid translation and application of our innovative research.
